MiR-29 enables immune evasion of colon cancer by regulating fucosylation-mediated Ras-GTP signal in CD8+ T cells
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1252667 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Immune checkpoint blockade (ICB) therapies such as PD-1 antibodies has shown remarkable clinical success in the control of tumor growth, yet only a fraction of patients benefits from such therapy. As a result, there is increasing interest in boosting the effectiveness of ICB by combining it with other treatments. Objectives: Screening critical microRNAs that inhibit colon tumor growth in concert with ICB based on the effectiveness of immunotherapy and the gene expression levels in colorectal patients and revealing the regulatory mechanism.
2025-07-31 | GSE295030 | GEO
Project description:Cancer secretome is a reservoir for aberrant glycosylation. How therapies alter this post59 translational cancer hallmark and the consequences thereof remain elusive. Here we show that an elevated secretome fucosylation is a pan-cancer signature of both response and resistance to multiple targeted therapies. Large-scale pharmacogenomics revealed that fucosylation genes display widespread association with resistance to these therapies. In both cancer cell cultures and patients, targeted kinase inhibitors distinctively induced core fucosylation of secreted proteins less than 60 kDa. Label-free proteomics of N-glycomes revealed that fucosylation of the antioxidant PON1 is a critical component of the therapy66 induced secretome. Core fucosylation in the Golgi impacts PON1 stability and folding prior to secretion, promoting a more degradation-resistant PON1. Non-specific and PON1-specific secretome deglycosylation both limited the expansion of resistant clones in a tumor regression model. Our findings demonstrate that core fucosylation is a common modification indirectly induced by targeted therapies that paradoxically promotes resistance.
2023-04-05 | GSE160205 | GEO
Project description:Using microarray analysis, we identified a unique ras superfamily gene, termed RERG (ras-related and estrogen-regulated growth inhibitor), whose expression was decreased or lost in a significant percentage of primary human breast tumors that show a poor clinical prognosis. Importantly, high RERG expression correlated with expression of a set of genes that define a breast tumor subtype that is estrogen receptor-positive and associated with a slow rate of tumor cell proliferation and a favorable prognosis for these cancer patients. RERG mRNA expression was induced rapidly in MCF-7 cells stimulated by beta-estradiol and repressed by tamoxifen treatment. Like Ras, RERG protein exhibited intrinsic GDP/GTP binding and GTP hydrolysis activity. Unlike Ras proteins, RERG lacks a known recognition signal for COOH-terminal prenylation and was localized primarily in the cytoplasm. Expression of RERG protein in MCF-7 breast carcinoma cells resulted in a significant inhibition of both anchorage-dependent and anchorage-independent growth in vitro and inhibited tumor formation in nude mice. These features of RERG are strikingly different from most Ras superfamily GTP-binding pro-teins and suggest that the loss of RERG expression may contribute to breast tumorigenesis. Groups of assays that are related as part of a time series. Computed
2005-07-23 | E-GEOD-2987 | biostudies-arrayexpress
Project description:Aberrant activation of the RAS/MAPK signaling limits the clinical efficacy of several targeted therapies in acute myeloid leukemia (AML). In FLT3-mutant AML, the selection of clones harboring heterogeneous RAS mutations drives resistance to FLT3 inhibitors (FLT3i). RAS activation is also associated with resistance to other AML targeted therapies, including the BCL2 inhibitor venetoclax. Despite the critical need to inhibit RAS/MAPK signaling in AML, no targeted therapies have demonstrated clinical benefit in RAS-driven AML. To address this unmet need, we investigated the preclinical activity of RMC-7977, a multi-selective inhibitor of GTP-bound active [RAS(ON)] isoforms of mutant and wild-type RAS in AML models. RMC-7977 exhibited potent antiproliferative and pro-apoptotic activity across AML cell lines with MAPK-activating signaling mutations. In Molm-14 and OCIAML-3 cell lines, RMC=7977 downregulated expression of genesets involved in RAS/MAPK and PI3K/Akt/mTOR signaling, as well as MYC targets and cell cycle regulators.
2025-07-04 | GSE301645 | GEO
Project description:Disruption of Ras/cAMP signaling by perturbation of pathway elements and controlled cAMP concentration. All cultures grown in SC medium. Keywords: other
2005-10-01 | GSE2927 | GEO
Project description:Using microarray analysis, we identified a unique ras superfamily gene, termed RERG (ras-related and estrogen-regulated growth inhibitor), whose expression was decreased or lost in a significant percentage of primary human breast tumors that show a poor clinical prognosis. Importantly, high RERG expression correlated with expression of a set of genes that define a breast tumor subtype that is estrogen receptor-positive and associated with a slow rate of tumor cell proliferation and a favorable prognosis for these cancer patients. RERG mRNA expression was induced rapidly in MCF-7 cells stimulated by beta-estradiol and repressed by tamoxifen treatment. Like Ras, RERG protein exhibited intrinsic GDP/GTP binding and GTP hydrolysis activity. Unlike Ras proteins, RERG lacks a known recognition signal for COOH-terminal prenylation and was localized primarily in the cytoplasm. Expression of RERG protein in MCF-7 breast carcinoma cells resulted in a significant inhibition of both anchorage-dependent and anchorage-independent growth in vitro and inhibited tumor formation in nude mice. These features of RERG are strikingly different from most Ras superfamily GTP-binding pro-teins and suggest that the loss of RERG expression may contribute to breast tumorigenesis. Groups of assays that are related as part of a time series. Keywords: time_series_design
2005-07-23 | GSE2987 | GEO
Project description:To define the signalling of extracellular GTP as enhancer of myogenesis, we investigated if the gene expression profile of differentiated C2C12 cells (4 hours in DM) was affected by extracellular GTP. Two-condition experiment, GTP-treated C2C12 cells vs Control C2C12 cells at 4 h of differentiation. Biological replicates: 1 control, 1 GTP-treated cells, independently grown and harvested. One replicate per array.
2010-06-20 | E-GEOD-18584 | biostudies-arrayexpress
Project description:To define the signalling of extracellular GTP as enhancer of myogenesis, we investigated if the gene expression profile of differentiated C2C12 cells (4 hours in DM) was affected by extracellular GTP.
2009-10-29 | GSE18584 | GEO
Project description:To define the signalling of extracellular GTP as enhancer of myogenesis, we investigated if the gene expression profile of differentiated C2C12 cells (4 and 24 hours in SM) was affected by extracellular GTP.
2009-10-29 | GSE18531 | GEO
Project description:To define the signalling of extracellular GTP as enhancer of myogenesis, we investigated if the gene expression profile of differentiated C2C12 cells (4 and 24 hours in SM) was affected by extracellular GTP. Two-condition experiment, GTP-treated C2C12 cells vs Control C2C12 cells at 4 h and 24 h of differentiation. Biological replicates: 1 control, 1 GTP-treated cells, independently grown and harvested. One replicate per array.
2010-06-20 | E-GEOD-18531 | biostudies-arrayexpress